Clinical trial · Observational
Oncologic Safety and Lymphadenectomy in Parenchyma-Sparing Resection for SPN
Parenchyma-Sparing Resection for Pancreatic Solid Pseudopapillary Neoplasm: Oncologic Safety and Role of Lymphadenectomy in a Prospective Cohort Study
NCT07592663CI-TRIAL-00111879PSR for SPNcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Solid pseudopapillary neoplasm (SPN) of the pancreas is a low-grade malignant tumor primarily treated with surgical resection. However, the oncologic safety of parenchyma-sparing resection (PSR) and the necessity of lymphadenectomy remain debated. This prospective cohort study evaluates these aspects based on long-term outcomes.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Tumor, Benign | Benign Pancreatic Neoplasm | ALIAS | 0.90 |
| Solid Pseudopapillary Tumor of the Pancreas | Solid Pseudopapillary Neoplasm of the Pancreas | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Parenchyma-sparing resection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- PSR group
- description
- Patients with solid pseudopapillary neoplasm who underwent parenchyma-sparing resection (PSR). PSR included enucleation (EN), duodenum-preserving pancreatic head resection (DPPHR), central pancreatectomy (CP), and spleen-preserving distal pancreatectomy (SPDP).
- interventionNames
- Procedure: Parenchyma-sparing resection
- label
- OR group
- description
- Patients with solid pseudopapillary neoplasm who underwent oncologic resection (OR). OR included pancreatoduodenectomy (PD), distal pancreatectomy with splenectomy (DPS), and total pancreatectomy (TP).
Primary outcomes (5)
- measure
- Reoperation rate
- timeFrame
- Within 90 days after surgery.
- description
- Reoperation rate within 90 days after surgery.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. age between 18 and 75 years, regardless of gender; 2. patients with solid pseudopapillary neoplasm of the pancreas; 3. patients with an ECOG performance status of 0 or 1; 4. successfully received sugary (open or laparoscopic or robotic) Exclusion Criteria: (1) Pediatric patients with SPN under 14 years of age, or elderly patients over 80 years of age; (2) Reoperative resection for recurrent or metastatic SPN; (3) presence of distant metastasis or concomitant malignant tumors before surgery; and (4) loss to follow-up within 90 days after surgery.
References
Publications (4)
- RESULTBolm L, Nebbia M, Wei AC, Zureikat AH, Fernandez-Del Castillo C, Zheng J, Pulvirenti A, Javed AA, Sekigami Y, Petruch N, Qadan M, Lillemoe KD, He J, Ferrone CR; PAncreatic Neuroendocrine Disease Alliance (PANDA). Long-term Outcomes of Parenchyma-sparing and Oncologic Resections in Patients With Nonfunctional Pancreatic Neuroendocrine Tumors <3 cm in a Large Multicenter Cohort. Ann Surg. 2022 Sep 1;276(3):522-531. doi: 10.1097/SLA.0000000000005559. Epub 2022 Jun 27. PMID 35758433
- RESULTLiu Q, Dai M, Guo J, Wu H, Wang W, Chen G, Hu Y, Han X, Xu Q, Zhang X, Yang S, Zhang Y, Kleeff J, Liao Q, Wu W, Liang Z, Zhang T, Zhao Y. Long-term Survival, Quality of Life, and Molecular Features of the Patients With Solid Pseudopapillary Neoplasm of the Pancreas: A Retrospective Study of 454 Cases. Ann Surg. 2023 Dec 1;278(6):1009-1017. doi: 10.1097/SLA.0000000000005842. Epub 2023 Apr 10. PMID 37036095
- RESULTBersot TP, Vega GL, Grundy SM, Palaoglu KE, Atagunduz P, Ozbayrakci S, Gokdemir O, Mahley RW. Elevated hepatic lipase activity and low levels of high density lipoprotein in a normotriglyceridemic, nonobese Turkish population. J Lipid Res. 1999 Mar;40(3):432-8. PMID 10064731
- RESULTLi J, Zheng H, Zhang X, Pan B, Lu J, Zhou L, Zhang T, Dai M, Guo J, Wang W, Han X, Xu Q, Hua Y, Kleeff J, Wu H, Liang Z, Liu Q, Liao Q. Molecular profiling reveals the malignant potential in solid pseudopapillary neoplasms of the pancreas. Cancer Lett. 2025 Aug 10;625:217788. doi: 10.1016/j.canlet.2025.217788. Epub 2025 May 15. PMID 40381684